Antileishmanial properties of a drug candidate and its back-up on cutaneous leishmaniasis experimental models

• Auteur / Autrice : Daniel Amiteye
• Direction : Philippe Loiseau, Sébastien Pomel
• Type : Projet de thèse
• Discipline(s) : Microbiologie
• Date : Inscription en doctorat le 01/10/2020
• Etablissement(s) : université Paris-Saclay
• Ecole(s) doctorale(s) : École doctorale Innovation thérapeutique : du fondamental à l'appliqué (Châtenay-Malabry, Hauts-de-Seine ; 2015-....)
• Partenaire(s) de recherche : Laboratoire : Biomolécules : Conception, Isolement et Synthèse
• Partenaire(s) de recherche : Référent : Université Paris-Saclay (2020-....)

Mots clés

Mots clés libres

Antileishmanial

Drug candidate

Cutaneous leishmaniasis

Résumé

Cutaneous leishmaniasis is presently an emerging parasitic disease in Ghana with several outbreaks (Kwakye-Nualo et al., Int. J. Parasitol., 45 : 679-684, 2015 ; Nzelu et al., PLoS Negl. Trop. Dis., 8 :e2630, 2014). As a consequence, the training of Ghanean researchers in this field is necessary. Thus, we propose a topics of drug discovery integrating classical strains and Leishmania clinical isolates from Ghana responsible for cutaneous leishmaniasis. A drug candidate and its back-up from CEA Saclay with an original mechanism of action preventing the formation of the parasitophorous vacuole in the host cell, have been selected on the Leishmania infantum/BALB/c mice model. The present project aims to investigate the potential of these compounds for the treatment of cutaneous leishmaniasis through in vitro and in vivo evaluation on murine models.